The selection of a contract research organization (CRO) marks a pivotal step in the company’s strategy to streamline the clinical development of its pipeline. By targeting multiple conditions simultaneously, the firm aims to utilize what it describes as a resource-efficient mechanism for drug testing. This multi-indication approach follows a safe to proceed letter issued by the U.S. Food and Drug Administration in October 2025, clearing the path for human trials.
In section Market Quotes
Polaryx Therapeutics Jumps 66% on Phase 2 Trial Expansion Plans
Polaryx Therapeutics shares surged 66% to $4.01 after the biotechnology firm appointed a contract research organization to lead a Phase 2 clinical trial for its lead candidate, PLX-200. The study will evaluate the drug’s safety and efficacy across four distinct lysosomal storage disorders.
Management expects to initiate the Phase 2 study during the first half of 2026. The trial is designed to assess the clinical activity of PLX-200, a compound specifically engineered to address the underlying mechanisms of rare genetic metabolic diseases.
Comments (0)
No comments yet. Be the first!